the changing role of allosct in dlbcl in the era of novel agents
Published 1 year ago • 73 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
3:22
advances and unanswered questions in aml: novel agents, mrd assessment, and immunotherapy
-
1:41
novel therapies for high-risk mds
-
1:32
novel drug targets for mds
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
16:35
key highlights in mpns at ash 2023: novel agents & combinations, ongoing clinical trials, and more
-
9:25
mgus diagnosis: a step-by-step approach
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:01
exploring the biological mechanisms driving mbl progression to cll
-
1:17
exciting novel treatments being developed for mds
-
1:04
exciting updates in mf: novel targets and agents
-
2:10
using the innate immune system to treat mds & the value of novel immunotherapies
-
0:55
the role of rna modifications in mds and aml
-
2:43
novel therapies in the future of mds treatment
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
3:24
novel agents for the management of r/r myeloma
-
3:01
novel promising agents and clinical trials in amyloidosis
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
3:02
novel treatments and ongoing clinical trials for wm: targeted agents and immunotherapies
-
1:36
clinical trials evaluating novel agents in mds: select-mds-1